Akums Drugs and PharmaceuticalsNSE:AKUMS +4.05%39 ROE % is 10.21% as of Mar. 2026, which is 7% below its 10-year median of 10.95. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 935 Drug Manufacturers companies, Akums Drugs and Pharmaceuticals ranks better than 57.22% on this metric.
NSE:AKUMS'
s ROE % Range Over the Past 10 Years
Min: -33.52 Med: 10.95 Max: 18
Current: 8.05
During the past 6 years, Akums Drugs and Pharmaceuticals's highest ROE % was 18.00%. The lowest was -33.52%. And the median was 10.95%.
NSE:AKUMS's ROE % is ranked better than 57.22% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs NSE:AKUMS: 8.05
Akums Drugs and Pharmaceuticals (NSE:AKUMS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Akums Drugs and Pharmaceuticals ROE % Related Terms
Akums Drugs and Pharmaceuticals ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's ROE % distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a ROE % of 10.21% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Akums Drugs and Pharmaceuticals and its competitors. This is near median its historical median of 10.95. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #400 out of 935 companies in the Drug Manufacturers industry, placing it in the top 42.8%.
Is Akums Drugs and Pharmaceuticals' ROE % too high?
Akums Drugs and Pharmaceuticals' current ROE % of 10.21% is near median its 10-year median of 10.95. The Drug Manufacturers industry median ROE % is 6.00. Akums Drugs and Pharmaceuticals' value of 10.21% is 70.2% above this industry median. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #400 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #400 out of 935 companies for ROE %. This puts Akums Drugs and Pharmaceuticals in the upper half of its industry. The industry median ROE % is 6.00. Akums Drugs and Pharmaceuticals' value of 10.21% is 70.2% above this benchmark. While the company's 10-year median is 10.95 vs. the industry median of 6.00, Akums Drugs and Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current ROE % of 10.21% is 70.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Akums Drugs and Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current ROE % is 10.21%, which is near median its own 10-year median of 10.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current ROE % of 10.21%. The current ROE % is 10.21%, which is near median its 10-year median of 10.95 and 70.2% above the Drug Manufacturers industry median of 6.00. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current ROE % is 10.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Business Description
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score
Get the complete analysis for NSE:AKUMS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
